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Exome and immune cell score analyses reveal great variation
within synchronous primary colorectal cancers
Ulrika A. Hänninen1,2, Erkki-Ville Wirta3, Riku Katainen1,2, Tomas Tanskanen1,2, Jiri Hamberg1,2, Minna Taipale4, Jan Böhm5,
Laura Renkonen-Sinisalo6, Anna Lepistö6, Linda M. Forsström1,2, Esa Pitkänen1,2,7, Kimmo Palin1,2, Toni T. Seppälä6, Netta Mäkinen1,2,
Jukka-Pekka Mecklin8,9 and Lauri A. Aaltonen1,2
BACKGROUND: Approximately 4% of colorectal cancer (CRC) patients have at least two simultaneous cancers in the colon. Due to
the shared environment, these synchronous CRCs (SCRCs) provide a unique setting to study colorectal carcinogenesis.
Understanding whether these tumours are genetically similar or distinct is essential when designing therapeutic approaches.
METHODS: We performed exome sequencing of 47 primary cancers and corresponding normal samples from 23 patients.
Additionally, we carried out a comprehensive mutational signature analysis to assess whether tumours had undergone similar
mutational processes and the first immune cell score analysis (IS) of SCRC to analyse the interplay between immune cell invasion
and mutation profile in both lesions of an individual.
RESULTS: The tumour pairs shared only few mutations, favouring different mutations in known CRC genes and signalling pathways
and displayed variation in their signature content. Two tumour pairs had discordant mismatch repair statuses. In majority of the
pairs, IS varied between primaries. Differences were not explained by any clinicopathological variable or mutation burden.
CONCLUSIONS: The study shows major diversity within SCRCs. Rather than rely on data from one tumour, our study highlights the
need to evaluate both tumours of a synchronous pair for optimised targeted therapy.
British Journal of Cancer (2019) 120:922–930; https://doi.org/10.1038/s41416-019-0427-4
BACKGROUND
Colorectal cancer (CRC) is the third most common cancer type and
the fourth leading cause of cancer deaths worldwide.1 Around 4%
of CRC patients have more than one simultaneous primary
colorectal carcinoma.2–4 These synchronous CRCs (SCRCs) are
more common in men as CRC in general, but the male–female
ratio is even higher than with solitary tumours.3,4 Compared to
solitary CRCs, clinicopathological studies have associated SCRC
more often with mucinous histology, right-sided tumours,
presence of adenomas, and sessile serrated adenomas as the
precursor.5 There is no consensus on the correlation between the
age at diagnosis and SCRC. Studies tend to support a higher age at
presentation in SCRC than with solitary tumours.6,7 SCRC prog-
nosis compared to that of solitary tumours vary between studies
with contradicting results.2,4,5,7,8 The majority of CRCs are
microsatellite stable (MSS), whereas about 15% of CRCs display
microsatellite instability (MSI).9 MSI tumours have a defective DNA
mismatch repair (MMR) system and thus exhibit a remarkably high
mutation burden compared to MSS tumours. Some studies have
shown that MSI tumours are more frequent in SCRC than in
solitary colorectal carcinomas,5,8 but this may be due to under-
lying Lynch syndrome (LS).
SCRC has been associated with predisposing conditions, such as
LS, familial adenomatous polyposis, and inflammatory bowel
disease.6,10–12 According to a large-scale study, such conditions
account for only slightly more than 10% of SCRC cases.3 The
pathological and clinical features of the SCRCs have been widely
studied.2,3,5 The underlying molecular mechanisms in SCRC,
however, have not been thoroughly examined. Genetic research
has mainly focused on single factors such as MSI status and known
cancer genes, including APC, KRAS, and BRAF, with varying
results.8,13–15 Thus far, there has been only a few exome-wide
studies on SCRC and one study including whole-genome
sequencing data of a SCRC case.16–19 In general, these studies
have supported the idea of independent origins of synchronous
tumours. Another hypothesis underlying SCRC, in addition to a
common progenitor, is the field effect.8,20 The molecular basis for
the field effect has been proposed to be e.g. massive exposure to
a carcinogen or genetic predisposition through mosaicism in a
patient. Epigenetic alterations, such as low LINE-1 methylation, O6-
methylguanine-DNA methyltransferase promoter methylation, or
other CpG island methylation in the colonic mucosa, and
damaging germline mutations in immune-related genes leading
to an inflammatory microenvironment that might favour
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tumorigenesis, have also been suggested as potential causative
mechanisms.16,21–23
By exome sequencing the tumour pair and corresponding
normal sample from 23 patients, the largest exome set of SCRCs
thus far, we studied comprehensively the extent of genetic
overlap within the synchronous tumours, including mutational
signatures, and searched for possible germline predisposing
genes. In addition, we evaluated the lymphocyte levels (immune
cell score, IS) in the tumours using the same principle as
Immunoscore®, which derives from the densities of CD3+ and
CD8+ lymphocytes in the tumour centre and invasive margins, a
new prognostic marker in CRC. Immune score combined with TNM
classification and/or defined MMR status has been suggested to
predict survival and response to therapy in colon cancer.24–27 It is
not known how immune responses and thus immune cell levels
vary between synchronous tumours within a patient. Knowledge
on the molecular basis of SCRC provides more insight on how
these tumours arise and allows the development of more
personalised treatments.
MATERIALS AND METHODS
Patient cohort
The study set composed of 23 CRC pairs and their corresponding
normal tissue samples. All patients were Finnish (white Caucasian)
of which 20 patients were derived from a consecutive, population-
based series of 1088 CRCs (Suolisyöpä Keski-Suomi) from
Jyväskylä, Finland. In addition, 3 SCRC patients were derived from
an in-house population-based series of 1042 CRCs collected
1994–199828,29 and a subsequent, ongoing series of CRCs
collected since 1998 (unpublished data). We included only SCRC
patients from which we had material from both tumours. For two
of the in-house cases, we utilised readily available whole-genome
sequencing data for one tumour and normal sample, while exome
sequencing the other tumour. All relevant medical records were
available for all the cases.
Some previous studies have considered lesions occurring within
6 months of the primary excisional operation as synchronous.
Here we defined the term synchronous by having at least two
tumours diagnosed and operated simultaneously. These tumours
were all separated by normal colonic mucosa and defined as
independent primary tumours both by a surgeon and a
pathologist. All except one patient (sync_11 who belongs to a
LS family with a pathogenic MLH1 germline variant) were assumed
sporadic. None of the patients had a known history of
inflammatory bowel disease. Four patients had three simultaneous
cancers. From one of them (sync_11) all three tumours were
included in this study.
Samples were mainly formalin-fixed and paraffin-embedded
(FFPE) with a few fresh frozen tissue samples (59 FFPE and 11 fresh
frozen). MMR status was determined by immunohistochemistry
staining (Suolisyöpä Keski-Suomi samples) and MSI status with
microsatellite markers (in-house samples). The division of MSS and
MSI tumours was confirmed by the exome data (see Supplemen-
tary Table 1).
DNA extraction
For genomic DNA extraction from FFPE blocks, we used a standard
phenol-chloroform isolation method, and from fresh frozen tissue,
non-enzymatic DNA extraction protocol. DNA concentration was
determined with the Qubit double-stranded DNA BR Assay Kit
(Thermo Fisher Scientific, Waltham, MA, USA) and purity with
NanoDrop 8000 (Thermo Fisher Scientific).
Exome sequencing
Exome libraries were prepared with KAPA Hyper Prep Kit (Kapa
Biosystems, Wilmington, MA, USA). Coding exons and untrans-
lated regions of the genome (94 megabases) were enriched with
the NimbleGen SeqCap EZ Exome Library v3 Kit (Roche
NimbleGen, Madison, WI, USA). Paired-end sequencing with
read lengths of 75 base pairs with a median depth of 37×
(interquartile range (IQR), 33× to 40×) was performed by
Illumina HiSeq 2000/4000 (Illumina Inc., San Diego, CA, USA) in
Karolinska Institutet, Sweden. The median fraction of the exome
with at least 10× coverage was 84%.
Read mapping and variant calling
The quality of raw sequencing data was examined using FastQC
v.0.10.0 (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) and
QualiMap v.2.1 (http://qualimap.bioinfo.cipf.es/).30 3′ ends of reads
with high adapter similarity were removed with Trim Galore! v.0.3.07
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/)
and trimmed reads were mapped to the integrated 1000 Genomes
Phase 2 GRCh37/hg19 reference assembly with Burrows-Wheeler
Aligner (BWA)–MEM version 0.7.12 (http://bio-bwa.sourceforge.net/).31
Overlapping read pairs were clipped using BamUtil version 1.0.13
(http://genome.sph.umich.edu/wiki/BamUtil#Releases) ClipOverlap.
Duplicate reads were removed using Samtools v.1.0 (http://www.
htslib.org/)32 rmdup on both paired-end and single-end reads to
correct for e.g. FFPE-derived sequencing artefacts. Aligned reads were
locally realigned using the Genome Analysis ToolKit (GATK) v.3.5
(https://www.broadinstitute.org/gatk/) IndelRealigner33 and base
scores were recalculated with GATK BaseRecalibrator. After realign-
ment the final single-nucleotide variant (SNV) and indel calls were
made with the GATK HaplotypeCaller using a variant quality threshold
of 1.0.
Somatic variant analysis
The tumour data were filtered against the normal tissue data to
remove germline variants. We refined remaining variant calls
against a pooled set of whole-genome sequencing data (median
~40× coverage/sample) from 10 blood samples by excluding any
SNV call, which was found in three or more reads in the pooled
data. Indel calls were filtered out if two or more samples had more
than three reads calling an indel at 100 base pairs (read length)
from the indel locus. This step was done to exclude low allelic
fraction artefacts in regions prone to sequencing errors. Only
variants within the targeted region of NimbleGen SeqCap EZ
Exome Library v3 Kit were analysed.
A comparative analysis and visualisation tool BasePlayer34 was
utilised to visualise and analyse the data. The criteria to call a
mutation included total coverage of at least four reads at the
mutation locus with the GATK quality score at least 20, to filter out
false calls that derive e.g. from FFPE. For indels, the criteria
required additionally a minimum of 10% mutant allele fraction.
Indels called with the minimum mutant allele fraction (n= 31) had
a total coverage of 50 or higher. In addition, 1000 Genomes phase
1 pilot-style callability region mask was used to filter out possible
false calls located in regions with poor callability.35 The
comparison of the mutation profiles to determine the amount
of genetic overlap in each tumour pair took into account the
number of shared variants that occurred in the exact same
positions in the coding region.
Germline variant analysis
The normal tissue data were filtered against The Genome
Aggregation Database (gnomAD, http://gnomad.broadinstitute.
org/).36 Germline variants with allele frequency more than 0.001 in
the whole gnomAD, 0.001 in population-specific Finnish gnomAD
exome set (n= 85,202), and 0.01 in population-specific Finnish
genome set (n= 1747) were excluded. Indel calls were refined
similarly as in the somatic variant analysis. The criteria to call a
variant included coverage of at least 10 reads, GATK quality score
of at least 20, and a minimum of 20% mutant allele fraction. Only
coding variants within the targeted region of NimbleGen SeqCap
EZ Exome Library v3 Kit were analysed.
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Mutation signature analysis
Mutational signatures were modelled in 96-dimensional space
representing all single base mutations in one base pair context,
possibly reversely complemented such that the mutation source
base is always cytosine or thymine. Each tumour is represented by
an integer vector of counts of such somatic mutations. The
mutation count in a given sequence context was modelled as
Poisson distributed random variable with the rate parameter
being a linear combination of four distinct Dirichlet(1) distributed
mutational signatures: one specific to patient, one related to MSI,
and two tumour-specific processes. The prior for the signature
weights was half Cauchy(100). The modelling and Markov chain
Monte Carlo (MCMC) sampling was performed with pymc3
library.37 We drew 10,000 MCMC samples from 10 independent
chains ignoring 500 burn-in samples and thinning with factor 100.
Signature comparison to Alexandrov et al. was performed using
Maximum-A-Posteriori probability signatures.38 To calculate the
variation of signature contents between tumours mixed linear
model “Y=m+MMRstatus+ Individual+ Tumour” was used on
MAP estimates of signature exposure proportion Y, explained by
fixed effects of intercept m and MMR status and random effects of
Individual and Tumour.
Ingenuity pathway analysis
Ingenuity pathway analysis (IPA) version 44691306 was used to
determine the frequency of known cancer pathways affected
within the tumour pairs. IPA was utilised to define genes linked to
each pathway. All genes with at least one non-synonymous
mutation were included in the analysis.
Sanger sequencing
The reported mutations in XPNPEP1, FAM133A, and GPR98 were all
validated successfully with Sanger sequencing (recall rate 100%).
The corresponding normal samples were also sequenced to
confirm somatic nature of mutations. Primers were designed using
Primer3Plus.39 Regarding FFPE tissue samples, three independent
PCR reactions were performed to ensure consistency of the
observations. Sequencing reactions were performed with the Big
Dye Terminator v.3.1 kit (Applied Biosystems, Foster City, CA, USA)
on an ABI3730 Automatic DNA Sequencer (FIMM Technology
Center and DNA sequencing and Genomics laboratory, Institute of
Biotechnology, Helsinki, Finland). The sequence graphs were
analysed both with the Mutation Surveyor –software (version
v4.0.8, Softgenetics, State College, PA) and manually.
Immune cell score determination
Immunohistochemical staining with CD3 (Novocastra, NCL-L-CD3,
clone PS1) and CD8 (Thermo Scientific, RM-9116, clone SP16)
antibodies was performed as previously described.26 Stained
whole-section slides were digitally scanned with NanoZoomer-XR
(Hamamatsu Photonics K.K., Hamamatsu City, Japan), and
positively stained T-cell counts were calculated using QuPath
image analysis software.40
The IS consists of CD3 and CD8 lymphocyte counts from tumour
centre and invasive margin. Width of the invasive margin was
considered to span 360 μm into the tumour and 360 μm into the
healthy tissue from the visible tissue frontier as presented by
Hermitte.41 This area was marked with an annotation brush tool. A
representative area within the tumour centre was selected for cell
calculation. From both CD3 and CD8 stainings mean analysed area
was 10.0 mm² for invasion margin and 13.6 mm2 for tumour
centre. The sections were determined to have either high or low
lymphocyte count (number of cells/mm2). To form IS we used the
same receiver-operating characteristic (ROC) curve-based cut-off
values that were used in a previous study with a larger study
population.26 Areas with low lymphocyte count were scored as 0
and areas with high lymphocyte count were scored as 1, so the
following IS gained a value from 0 to 4. IS is composed using the
same basic principles as Immunoscore® with the difference of
manually selected representative tumour areas and invasive
margins, ROC curve-based cut-off values, and the use of open
source image analysis software.
Statistical analysis of IS data
We utilised R version 3.5.1 to perform statistical analyses.
Spearman’s rank correlation coefficient was used to evaluate the
correlation of IS within tumour pairs, excluding one case with
three tumours (sync_11). Considering that tumours from the same
individual may not be independent, we applied generalised
estimating equations (GEEs) with ordinal response to examine the
association between IS and clinicopathological variables.42 The
ordLORgee function from the multgee package was used to fit
GEE models with uniform local odds ratios and cumulative logit
link.43 P-value < 0.05 was regarded as statistically significant. All
reported P-values are two-sided.
RESULTS
Cohort characteristics
We analysed a total of 47 tumours from 23 patients. Table 1
presents the clinicopathologic features of these cases. The
majority of patients (18/23, 78%) were male. The median age at
surgery was 72 years (range, 48–83 years). Majority of the
tumours (31/47, 66%) were located on the left side of the
colorectum (splenic flexure, descending or sigmoid colon, or
rectum), whereas 16/47 (34%) were right-sided (caecum,
ascending, or proximal transverse colon). Altogether 18/23
(78%) tumour pairs resided on the same side, the majority (13/
18, 72%) being left-sided. Eighteen tumour pairs were MSS-MSS,
three MSI-MSI, and two MSS-MSI. Four patients had an
additional tumour (of which one was included in the study) in
the colorectum and 18 patients presented with at least one
synchronous adenoma.
Mutation spectrum
Exome sequencing analysis identified 18,134 somatic coding
mutations across all samples. The most common transition type in
the tumours was C>T that accounted for 60% of all the detected
mutations. The median number of non-synonymous mutations
per sample was 88.5 in MSS tumours (IQR, 60.3–120) and 933 in
MSI tumours (IQR, 637–1197). There was variation in the number
of non-synonymous mutations within tumour pairs. The median
difference per MSS-MSS tumour pair was 44 non-synonymous
mutations (IQR, 15.5–71.8). The mutation count within the three
MSI-MSI pairs differed by 193, 359, and 902 mutations (sync_11
with three tumours having largest difference between lowest and
highest).
Lack of genetic overlap within tumour pairs points to separate
origins
The majority of the mutations were unique within tumour pairs
(Fig. 1). Out of 23 pairs, only 5 (22%) shared at least one exact
same mutation within paired lesions (Supplementary Table 2). In
three of these pairs the tumours shared the same driver mutation
either in BRAF, APC, or ACVR2A (Fig. 1). Altogether, shared
mutations accounted for 0.4–1.1% of the mutations found within
the five pairs. Of these pairs, two were MSS-MSS that shared one
mutation per pair: s956 in APC (R213X) and c110 in GPR98
(S4503C). The other three pairs were MSI-MSI that shared 12–39
mutations. All except two of these shared variants (BRAF hotspot
V600E in sync_4 and XPNPEP1 R204H in sync_11 (tumours
sync_11–2 and sync_11–3)) were frameshift mutations. One of
these frameshift mutations, shared by two sync 11 tumours, was in
RPL22, a gene that was recently reported to be frequently mutated
in SCRC.18 This mutation was found altogether in 5 out of 47
tumours (11%), all of which were MSI.
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Table 1. Cohort characteristics
Patient Sex Age Tumour Location Histology Grade MSI TNM T size (cm) Adenomas
s894 M 79 s894–1 Descendens ac 2 MSS T2N0M0 6 Yes
s894–2 Descendens ac in situ 2 MSS Tis 1.2
c440 M 83 c440–1 Border of rectosigma ac in situ 1 MSS Tis NA Yes
c440–2 Caecum ac 3 MSI T3N0M0 4.5
sync_1 M 82 sync_1–1 Caecum ac 3 MSS T2N0M0 3.5 No
sync_1–2 Transversum ac 3 MSS T3N0M0 5
sync_2 M 82 sync_2–1 Rectum ac 2 MSS T4N0M1 4.3 Yes
sync_2–2 Rectum ac in situ 1 MSS Tis NA
sync_3 F 67 sync_3–1 Rectum ac 2 MSS T3N1M0 NA Yes
sync_3–2 Rectum ac 2 MSS T1 NA
s75 M 71 s75–1 Rectum ac muc 3 MSS T3N0M0 4 Yes
s75–2 Caecum ac 2 MSS T3N0M0 5
s1268 M 66 s1268–1 Ascendens MANEC 4 MSS T3N2M0 5.2 Yes
s1268–2 Sigma ac 2 MSS T3N1M1 4
s882 F 67 s882–1 Rectum ac 2 MSS T1 1 No
s882–2 Caecum ac 2 MSS T4N0M0 2
sync_4 M 78 sync_4–1 Ascendens ac muc 3 MSI T3N0M0 11 Yes
sync_4–2 Ascendens ac muc 3 MSI T3N0M0 8
s387 M 62 s387–1 Flexura lienalis ac 1 MSS T3N1M1 3.5 NA
s387–2 Flexura lienalis ac 1 MSS T3N1M1 8
sync_6 M 72 sync_6–1 Caecum ac 2 MSS T4N1M0 4.1 Yes
sync_6–2 Ascendens ac 2 MSS T2N0M0 4.7
s483 F 81 s483–1 Caecum ac muc 3 MSI T3N2M0 9 Yes
s483–2 Ascendens ac 1 MSI T1 1.5
s956 M 76 s956–1 Rectum ac 2 MSS T3N1M0 6 Yes
s956–2 Sigma ac 2 MSS T3N1M0 4
s404 M 61 s404–1 Sigma ac 2 MSS T1N1M0 3.4 Yes
s404–2 Sigma ac 2 MSS T2N1M0 5.5
sync_7 M 72 sync_7–1 Rectum ac 2 MSS T2N0M0 4 Yes
sync_7–2 Sigma ac 2 MSS T1 4
sync_9 M 80 sync_9–1 Rectum ac 2 MSS T2N0M0 3 Yes
sync_9–2 Sigma ac 2 MSS T1 NA
sync_10 M 59 sync_10–1 Rectum ac 2 MSS T3N1M0 4 No
sync_10–2 Sigma ac 2 MSS T4N1M0 4.5
sync_11 M 48 sync_11–1 Ascendens ac 2 MSI T3N0M0 3.8 Yes
sync_11–2 Ascendens ac 2 MSI T3N0M0 11
sync_11–3 Ascendens ac 2 MSI T1N0M0 1
s1036 M 77 s1036–1 Sigma ac 2 MSS T4N0M0 12 Yes
s1036–2 Sigma ac 2 MSS T1N0M0 1.7
s1283 F 75 s1283–1 Caecum ac 2 MSI T3N0M0 3.5 Yes
s1283–2 Sigma ac NA MSS T4N2M0 2.5
c110 M 49 c110–1 Rectum ac 2 MSS T3N0M0 5 Yes
c110–2 Descendens ac 2 MSS T3N0M0 3.2
c117 F 83 c117–1 Descendens ac 2 MSS T3N1M0 7.5 Yes
c117–2 Rectum ac 2 MSS T3N0M0 5
s934 M 51 s934–1 Rectum ac 2 MSS T2N0M0 4 No
s934–2 Sigma ac 2 MSS T3N2M0 5
MSI microsatellite unstable, MSS microsatellite stable, ac adenocarcinoma, MANEC mixed adenoneuroendocrine carcinoma, ac muc adenocarcinoma
mucinosum, NA not available
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Next, we investigated whether tumours within a pair would
harbour mutations in the same known CRC genes. Discordance in
the mutation statuses was seen in many of these genes (Table 2,
Supplementary Table 3). Six out of 23 (26%) patients had a tumour
pair with one KRAS mutant and one wild type tumour. BRAF,
another clinically relevant gene, was mutated in one tumour of a
pair in 5/23 (22%) cases. This discordance was also evident in
other genes with possible clinical relevance, such as PIK3CA in 6/
23 (26%) and PTEN in 3/23 (13%). There were no known cancer
genes whose mutation patterns (mutated in both or only one
tumour of a patient) would have correlated across all pairs.
As expected, differences existed between MSS and MSI
tumours. Among the most frequently mutated genes in MSS
tumours were the known cancer genes APC (29/38, 76%), TP53
(21/38, 55%), KRAS (18/38, 47%), and TCF7L2 (7/38, 18%). In MSI
tumours, the most frequently mutated known cancer genes were
ACVR2A (9/9, 100%), MSH3 (5/9, 56%), FBXW7 (5/9, 56%), and BRAF
(5/9, 56%). CRC genes that were affected only in MSS tumours
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Fig. 1 Number of shared non-synonymous mutations in tumour pairs. Nearly all mutations were unique within paired tumours. Mutated APC,
KRAS, BRAF, and TP53 are marked in the tumours. There were only two cases where the paired tumours shared an exact same change in one of
these genes. Blue=microsatellite stable tumour; red=microsatellite unstable tumour
Table 2. Mutations in known cancer genes
Among the most frequently mutated genes in the whole sample set were the known cancer genes APC (33/47, 70%), TP53 (23/47, 49%), KRAS (18/47, 38%),
TCF7L2 (11/47, 23%), and ACVR2A (10/47, 21%). Exact same changes that occurred within four tumour pairs are marked with a hashtag. Sample names marked
with red refer to MSI tumours. Tumours might also contain additional mutations in these genes
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were KRAS and NRAS, whereas genes exclusive to MSI tumours
included MLH1, MLH3, MSH2, MSH3, and ERBB2.
Finally, we searched whether tumours within the pairs would
have other mutated genes in common. We focused on genes with
a truncating mutation in both tumours. Excluding the exact same
mutations and the known cancer genes listed above, there were
altogether four tumour pairs with such genes (Supplementary
Table 4). One MSI-MSS (s1283) pair displayed mutations in
FAM133A, whereas three MSI-MSI pairs shared each 3–34 genes
with truncating mutations, mainly consisting of frameshift
mutations.
Frequently mutated signalling pathways
Even though paired tumours harboured mutations in different
genes, we examined if these genes fell into similar pathways. We
characterised the most frequently mutated known cancer path-
ways (ATM, p53, Wnt/β-catenin, ERBB, PTEN, PI3K/AKT, ERK/MAPK,
and TGF-β) in tumour pairs (Supplementary Table 5). The number
of overlapping altered known pathways varied between one and
eight in a pair. There were six pairs where all the eight pathways
studied were mutated in both tumours. However, the number of
mutated genes associated with the pathways varied within the
tumour pairs.
Mutational signatures vary within tumour pairs
Next, we performed Bayesian mutation signature analysis for the
whole tumour set to see whether the tumours had experienced
different mutational processes. The mutation count in a given
sequence context was considered Poisson distributed with the
rate parameter being a linear combination of four distinct Dirichlet
distributed mutational signatures: one specific to patient, one
related to MSI, and two signatures, ts1 and ts2, that were tumour-
specific. The median number of mutations attributable to each
signature was 120, 1 581, 56.9, and 16.2, respectively. The patient-
specific signature was similar to the known age-related signature
1, reported by Alexandrov et al.44 The paired tumours harboured
similar numbers of mutations contributing to patient-specific
signature, which suggests that tumours within a patient were of
similar molecular age. The MSI signature was similar to signature 6,
the known MSI signature. The two tumour-specific signatures did
not clearly correspond to any of the known signatures.
For MSS tumours, 44–53% (95% credible interval (CI)) of
mutations could be attributed to tumour-specific mutational
processes in contrast to the processes intrinsic to the patient. For
MSI tumours, the tumour-specific proportion of somatic mutations
not attributed to MMR defect was probably (94.7% posterior
probability) lower, 27–51%, reflecting the decreased demand for
oncogenic mutations in the tumours beyond the ones produced
by MSI. Non-MSI-related tumour-specific signatures accounted for
85–71% fewer mutations in MSI tumours as they did in MSS
tumours. The MMR defect itself produced 5–8 times (95% CI) the
number of mutations that the patient-intrinsic and tumour-
specific, non-MSI mutation processes did.
To assess whether tumours within a patient resemble each
other more than other tumours in the set in general, the
proportion of variation of both tumour-specific signatures within
pairs were compared to the variation of these signatures in the
whole set. Patient identity explained approximately 35% of the
variance in relative contribution of ts1 mutation signature while
ts2 was entirely independent of the patient. Much of the variance
contribution of ts1 is explained by its association with freshly
frozen instead of formalin-fixed samples. After accounting for the
sample processing differences, only 8% of individual attributable
variance remains.
Looking at signature fractions, within 11/18 (61%) MSS-MSS
pairs, the order of most contributing signatures was the same
(Supplementary Figure 1). Of these, 9 pairs had the individual
signature as the biggest contributor, followed by ts1. In 2 pairs the
ts1 contributed the most and individual signature second. Within
7 MSS-MSS pairs the tumours displayed different order of
signature fractions. Location of the tumours did not explain the
variation in signature fractions within pairs. The majority (6/7,
86%) of the tumour pairs with different signature order located in
the same side.
Absence of common predisposing factors in SCRC
We analysed the germline variants of the 23 SCRC patients to
search for candidate susceptibility genes. The one known Lynch
syndrome patient (sync_11) had a germline mutation in MLH1
(rs193922370, c.454–1G>A). No other known predisposing factors
were found. Patient sync_4 harboured a missense variant in APC
L387V (rs760312726) in the germline. This variant was found in
five Finnish controls in gnomAD (minor allele frequency=
0.0002245). Careful examination of the patient records did not
reveal signs of familial adenomatous polyposis. When looking at
shared variants, we detected no clear candidate predisposing
genes in this sample set.
Immune cell counts vary between lesions
IS was assessed in 39 tumours from 19 SCRC patients (Supple-
mentary Table 6). The highest immunoscore category (IS4) was
observed most frequently (IS0, 15%; IS1, 10%; IS2, 15%; IS3, 18%;
and IS4, 41%). Equal immunoscores were observed in 3 patients
(3/19, 16%), whereas IS varied by one point in 6 patients (6/19,
32%), and by at least two points in 10 patients (10/19, 53%). Paired
tumours did not show a significant correlation in IS (P= 0.837).
Immune response was generally stronger in MSI tumours
compared to MSS tumours (78% MSI tumours with IS3 or IS4 vs.
53% MSS tumours with IS3 or IS4), although the difference was not
statistically significant (P= 0.103). Mutation count (P= 0.441),
gender (P= 0.397), or age at diagnosis (P= 0.339) did not seem to
explain the differences in IS. Also, there were no clear differences
in IS between left- and right-sided tumours (P= 0.161). Of note, all
the MSI tumours were right-sided and most of the MSS tumours
(77%) were left-sided. IS was not associated with mutation
signatures (individual signature, P= 0.288; signature ts1, P=
0.151; and signature ts2, P= 0.463).
Out of four pairs with the largest difference, three pairs resided
in the same segment (one pair on the right and two pairs on the
left side). Mutation statuses of the known cancer genes or
clinicopathological variables did not explain the IS variation within
patients. As an example, the tumours of a pair with the largest IS
difference (IS0 and IS4) were both MSI, located in ascending colon,
mucinous, and stage T3 tumours (Fig. 2). Similarly, within two
patients harbouring a MSS-MSI tumour pair with considerable
clinicopathological differences, IS differed maximally only by one
point. One pair was grade 1 MSS Tis (tumour in situ) with a low
number of mutations and IS3 from the recto-sigmoidal border and
grade 3 MSI T3 tumour with a high mutation load and IS4 from
caecum. The other pair was a MSS T4 tumour with a low number
of mutations and IS3 from sigmoid (grade unknown) and a grade
2 MSI T3 tumour with a high mutation load and IS3 from caecum
(Fig. 2). Also, when focusing on MSS-MSS pairs, variation was
present. There were two patients with left-sided MSS tumours and
similar mutation counts, but the IS differed by three points within
the pairs (Fig. 2).
DISCUSSION
To the best of our knowledge, this is the largest study to date to
use exome-wide genomic profiling combined with IS analysis to
determine similarities and differences within SCRC pairs. Based on
our exome data, only 5 out of 23 tumour pairs displayed one or
more exact same genomic changes within them. Of these, 3 were
MSI-MSI pairs where the tumours shared mutations almost
exclusively in repeated sequences and the remaining few in
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known mutation hotspots. The two MSS-MSS tumour pairs both
shared only one variant. One of these was a mutation hotspot in
APC, a well-known driver gene of intestinal tumorigenesis, shared
by coincidence or convergent evolution. Different mutation
patterns with few shared mutations strongly suggest these
tumours to have independent origins, supporting the theory of
a stochastic process in the genesis of SCRC. Similar interpretation
has been proposed in previous exome-level studies,16–18 whereas
one recent single-nucleotide polymorphism array-based study
suggested a subset of SCRCs to be monoclonal.45
Further evidence that SCRCs are independent in origin came
from the observed differences in the mutation statuses of known
CRC genes within tumour pairs, the phenomenon also seen in
previous studies.15–18 Additionally, the search for other genes with
a possibly damaging truncating mutation in both tumours of a
pair discovered mainly genes with frameshift mutations in
repeated sequences of MSI-MSI tumours, which probably have
arisen by chance due to the replication errors characteristic of
these type of tumours. Our data also suggest that SCRCs within
patients may utilise different signalling pathways. Genomic
diversity was evident in all tumour pairs, regardless whether the
patient had a known predisposition syndrome, a varying number
of adenomas, proximal or distal location of the tumours, or their
distance from each other. Thus, our results are not in accordance
with a previous study showing that similarities of molecular
genetic changes within SCRC pairs are related to proximity.14
Recently, RPL22 hotspot mutations were reported as frequent
events in SCRCs and proposed as a potential biomarker.18 These
mutations were present almost exclusively in MSI tumours. In this
study, RPL22 was mutated in 11% of tumours, all of which were
MSI being a frequent event in MSI tumours (5/9, 56%). Since RPL22
is a known MSI target gene and the hotspot in question is found
to be mutated significantly in MSI CRC,46–48 we hypothesise that
this phenomenon might be first and foremost related to MSI as
such, rather than SCRCs.
Altogether, 22% of SCRC patients had at least one MSI tumour.
The fraction of MSI tumours has been reported to be higher in
SCRC than that of solitary tumours (~15%), which our results also
support.8,9,49 The mutation frequencies of known CRC genes in
SCRCs resembled those seen in solitary tumours.50 Even genes
whose mutation frequencies have been reported to differ in SCRC,
such as BRAF, SMAD4, PIK3CA, and NRAS, showed no clear
difference in our study.8,17
Even though the SCRCs do not seem to share an origin, we
evaluated whether tumour pairs would have developed through
similar mutational processes by performing mutation signature
analysis. Paired tumours resembled each other somewhat more
than other tumours in the set when looking at tumour-specific
signature ts1, whereas ts2 did not differentiate between tumours
from same or different patients. Overall, signature contents
resembled each other within majority of the MSS-MSS tumour
pairs and also between patients. Over one-third of the tumour
pairs, however, harboured different mutation signature composi-
tions within a patient indicating these tumours have probably
undergone different mutational processes.
By evaluating IS, we were able to study the immune infiltrate in
both tumours of a patient to further characterise the differences and
similarities. Lymphocyte count has been shown to have a prognostic
value.26,27 The intratumour immune reaction varied between
patients and, in the majority of the cases (16/19, 84%), also within
tumour pairs. Variation was not clearly explained by any clinico-
pathologic feature, such as MSI status, mutation count, or tumour
location. It is thought that the immune reaction is affected by several
factors, such as the genetic background of the patient and the gut
microbiota.27 In addition, due to the intrapersonal heterogeneity
within the tumour immune reactions, our results support the notion
that also more local and tumour-specific reasons can exist, such as
the tumour microenvironment and the genetic content of the
tumour. For example, in addition to T cells other immune cells are
known to contribute to the behaviour of cancer cells.51
a b c d
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Fig. 2 Examples from CD3 and CD8 stainings showing part of tumour and invasive margins from synchronous microsatellite stable -
microsatellite unstable (MSS-MSI), MSS-MSS and MSI-MSI tumour pairs. a–dMSS-MSI tumour pair: MSS c440-1 with IS3 and MSI c440-2 with IS4
(a and b are CD3 and CD8 stainings from c440-1 and c and d CD3 and CD8 stainings from c440-2, respectively). e–h MSS-MSS tumour pair:
s404-1 with IS4 and s404-2 with IS1 (e and f are CD3 and CD8 stainings from s404-1 and g and h CD3 and CD8 stainings from s404-2,
respectively). i–lMSI-MSI tumour pair: sync 4-1 with IS0 and sync 4-2 with IS4 (i and j are CD3 and CD8 stainings from sync 4-1 and k and l CD3
and CD8 stainings from sync 4-2, respectively). Photos were captured with a ×20 magnification
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The study set consisted of solely Finnish patients, who as a
population have a unique genetic makeup due to strong genetic
isolation and relative small number of founder individuals, but in
addition to MLH1 variant in the LS case, no clear candidate
predisposition genes were discovered. We acknowledge that to
be successful this approach might require a larger sample size.
The study material included DNA derived from FFPE samples. We
have taken steps to ensure the efficient removal of possible false
calls caused by FFPE, however, we recognise that the data may
still contain some low-frequency artefacts. As a limitation of our
study, we were not able to examine the epigenetic changes, such
as gene methylation, or the non-coding genomic regions. Thus, it
remains unknown whether these factors could have an impact
on the tumour multiplicity. Another theorised factor thought to
contribute to synchronous tumorigenesis is the field effect. The
majority of the tumour pairs had a tendency to colonise the
same side of the colorectum, which might imply possible
regional field effect. Additionally, several patients had at least
one additional adenoma, which could also suggest a potential
field effect.
The variation within SCRC pairs may impact genetic testing
and therapeutic strategies. Our results strengthen the notion that
not only do the tumour pairs show variation in common drug
targets or predictors of therapy response, such as BRAF, KRAS,
and PIK3CA,13,52 but also in other potential targets or genetic
variants that might have an effect on treatment response.17,18
There were many tumour pairs where one tumour displayed
KRAS wild type and the other KRAS mutant status, a setting in
which only one of the tumours might respond to anti-epidermal
growth factor receptor therapy.53 Some patients displayed a
combination of MSS-MSI tumours where neoantigen levels might
vary between lesions. This might be relevant when considering
immune checkpoint inhibitors as potential treatment options.54
Incorporating IS as a measure of immune response might
provide further information on which tumours might react to
immune modulating therapy. Thus, therapeutic decisions espe-
cially regarding targeted therapies require careful planning and
it is paramount that all lesions within a patient should be
analysed for optimal outcome.
In conclusion, our study proposes a parallel evolution of SCRC
pairs without a common origin. This confirms previous observa-
tions and highlights the necessity to examine both tumours when
designing treatment. Our study elucidates further the genetic
background of SCRC and how immune responses vary between
the tumours, improving our understanding of the diversity within
the tumour pairs. Additional studies are still needed, however, to
shed further light on the causes for tumour multiplicity.
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